Are you prioritising FeNO testing in your asthma diagnosis and management plans? In October's newsletter we look at the benefits of early FeNO testing in revealing airway inflammation at the point-of-care, something which other tests may miss. Read on to learn more: https://lnkd.in/eQ2sd-Kk
FeNO by NIOX® USA
Medical Equipment Manufacturing
Morrisville, North Carolina 2,583 followers
NIOX VERO® is the gold standard FeNO testing device, and the world leader in FeNO testing
About us
NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma. NIOX VERO® provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings. The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals. Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma. References: 1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218. 2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1 3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173. 4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. 5. NIOX®. Data on File; MKT-DOF-007.
- Website
-
https://www.niox.com
External link for FeNO by NIOX® USA
- Industry
- Medical Equipment Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Morrisville, North Carolina
- Type
- Public Company
- Founded
- 2006
Locations
-
Primary
Get directions
1100 Perimeter Park Drive
Suite 114
Morrisville, North Carolina 27560, US
Employees at FeNO by NIOX® USA
Updates
-
Approximately 50% of asthma patients are non-adherent to medication. FeNO levels, a biomarker for airway inflammation, could reduce by up to 50% in 4 days when patients are adherent, signifying better asthma control. Uncover patient non-adherence and help improve patient outcomes with FeNO testing today: https://lnkd.in/ejH-fNGP
-
-
A simple and gentle way to test for asthma. Quickly find out what is going on in a patients lungs with FeNO testing. Non-invasive, straightforward testing at the point of care. Find out more: https://lnkd.in/evJmbJzR
-
-
FeNO by NIOX® USA reposted this
This year's theme for World Lung Day is "Clean Air and Healthy Lungs for All". It is a chance to raise awareness of lung conditions like asthma, and look at how solutions such as FeNO testing can help to support asthma patients lung health. Find out more: #WorldLungDay2024
-
FeNO by NIOX® USA reposted this
It's World Lung Day 2024! Did you know asthma affects over 300 million people globally? Learn how a quick and simple FeNO test can support your asthma care and help improve patient outcomes in our latest article.
Recognising World Lung Day 2024
NIOX® on LinkedIn
-
September is historically when asthma peaks. Join our Masterclass and learn how achieve more accurate diagnosis and better management of asthma. Available online and on our FeNO Learn mobile app. Access the Masterclass and much more all in one place today: https://lnkd.in/ejB5quUf
Discover our FeNO by NIOX® masterclasses today
niox.com
-
Did you know that 25% of asthma-related hospitalisations in children occur in September? Help get your paediatrics patients asthma under control with FeNO. FeNO testing for asthma is simple, non-invasive and requires minimal patient effort. Improve your patients asthma control during the September peak with FeNO by NIOX®: https://lnkd.in/efg8H9Di
-
-
It is week 38 of the year, which has historically been the week that hospitalizations and exacerbations peak for asthma. Check out our article for Top Tips on managing your patients asthma during the September peak, and help to get their asthma under control.
Back to school 2024: Top Tips on managing asthma through the September peak
FeNO by NIOX® USA on LinkedIn